Congress Materials

Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Gambacorti-Passerini C, Brummendorf TH, Abruzzese E, Kelly KR, Oehler VG, Garcia-Gutierrez V, Hjorth-Hansen H, Ernst T, Leip E, Purcell S, Luscan G, Viqueira A, Giles F, Hochhaus A December 11, 2021 ASH 2021 Hematology

Efficacy and Safety of Bosutinib in Previously Treated Patients With Chronic Myeloid Leukemia: Final Results From the BYOND Trial

View Presentation
Poster
Lesokhin AM, Iida S, Stevens D, Gabayan AE, Ma WD, Sullivan S, Raab MS December 11, 2021 ASH 2021 Hematology

MagnetisMM-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients With Relapsed or Refractory Multiple Myeloma

View Presentation View Video View Abstract Plain Language Summary
Poster
Özcan M, Cassaday RD, Singh P, Zarzycka E, Zhang X, Nègre E, Vandendries E, Altunas F December 11, 2021 ASH 2021 Hematology

The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study

View Presentation View Abstract Plain Language Summary
Poster
Pennesi E, Brivio E, Willemse ME, Huitema ADR, Chandra S, Vijayakumar A, Van Der Velden VHJ, Beverloo BH, Durairaj C, Viqueira A, Locatelli F, Motwani J, Bourquin JP, Bautista F, Rizzari C, Petit A, Lancaster D, Metzler M, Bertrand Y, Velasco P, Bukowkinski AJ, Krystal J, Van Der Sluis I, Van Tinteren H, Roth M, Hijiya N, Zwaan CM December 12, 2021 ASH 2021 Hematology

A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

View Presentation
Poster
Crawford R, Welch V, Shah R, Doward L, Truchan C December 12, 2021 ASH 2021 Hematology

A pilot study of the application of natural language interpretation to identify insights on acute lymphocytic leukemia and its treatment from social media data

View Presentation View Abstract Plain Language Summary
Poster
Ono T, Hino M, Matsumura I, Fujisawa S, Ishizawa K, Sakaida E, Sekiguchi N, Ono C, Aizawa M, Tanetsugu Y, Koide Y, Takahashi N December 12, 2021 ASH 2021 Hematology

Efficacy and Safety of Bosutinib in Japanese Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study

View Presentation View Abstract Plain Language Summary
Oral Presentation
Sebag M, Raje NS, Bahlis NJ, Costello CL, Dholaria B, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Lon HK, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Chu MP, Gasparetto C, Dalovisio A, Lesokhin AM December 13, 2021 ASH 2021 Hematology

MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted CD3-Engaging Bispecific Molecule, for Patients With Relapsed or Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Benjamin J. Samelson-Jones, Spencer K. Sullivan, John E. J. Rasko, Adam Giermasz, Lindsey A. George, Jonathan M. Ducore, Jerome M. Teitel, Catherine E. McGuinn, Amanda O'Brien; Ian Winburn, Lynne M. Smith, Amit Chhabra, Jeremy Rupon December 14, 2021 ASH 2021 Hemophilia

Follow-up of More Than 5 Years in a Cohort of Participants With Hemophilia B Treated With Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy

View Presentation
Poster
Hoffman JE, Sultan MB, Gundapaneni B, Witteles R December 14, 2021 ASH 2021 Transthyretin Amyloidosis (ATTR)

Free light chain levels in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT

View Presentation
Oral Presentation
Nathan Visweshwar, Thomas J. Harrington, Andrew D. Leavitt, Barbara A. Konkle, Adam Giermasz, Kimo C. Stine, Jeremy Rupon, Gregory Di Russo, Li-Jung Tseng, Maria de los Angeles Resa, Florence Ganne, Delphine Agathon, Frank Plonski, Didier Rouy, Bettina M. Cockroft, Annie Fang, Steven Arkin December 14, 2021 ASH 2021 Hemophilia

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A

View Presentation